ArticlePediatric blood & cancer2021
A safety and feasibility trial of
Article in Pediatric blood & cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Induction Regimens in High-Risk Neuroblastoma: Systematic Review of Response Rates and Toxicities.Cancer medicine · 2025Pooled it
- Radioligand therapy for pediatric patients with solid tumors.The British journal of radiology · 2026Review
- Development of novel GPC2-directed radiotheranostics and CAR T cell therapy for neuroblastoma.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- A radiopharmaceutical enhances CAR T cells against radio-sensitive and radio-resistant neuroblastoma by tumor sensitization and TME remodeling.Cell reports. Medicine · 2026Article
- Established and Emerging Therapies for High-Risk Neuroblastoma.Paediatric drugs · 2026Review
- Clinical applications and future directions of Iodine-131-Metaiodobenzylguanidine therapy in neuroblastoma: from salvage treatment to frontline integration.Annals of nuclear medicine · 2026Review
- Article
- Phase I Study ofJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Article
- Racial and Ethnic Survival Disparities Among Children With High-Risk Neuroblastoma: A Children's Oncology Group Report.JAMA network open · 2025Article
- An overview of current phase 3 radiopharmaceutical therapy clinical trials.Frontiers in medicine · 2025Review
- Molecular regulation and therapeutic targeting ofFrontiers in cell and developmental biology · 2025Review
- Therapeutic Innovation in Pediatric Neuroblastoma: Age and Stage-Specific Strategies from Prenatal to Early Childhood-A Review Article.Iranian journal of child neurology · 2025Review
- Identification and Characterization of Chemotherapy-Resistant High-Risk Neuroblastoma Persister Cells.Cancer discovery · 2024Article
- Patterns of recurrence after radiotherapy for high-risk neuroblastoma: Implications for radiation dose and field.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2024Article
- Review
- Robotic-assisted laparoscopic surgery for the treatment of Wilms' tumor in children: single-center experience and medium-term outcomes.Journal of robotic surgery · 2024Article
- Navigating new horizons: Prospects of NET-targeted radiopharmaceuticals in precision medicine.Theranostics · 2024Review
- The Impact ofChildren (Basel, Switzerland) · 2023Article
- Comparison of the different imaging modalities used to image pediatric oncology patients: A COG diagnostic imaging committee/SPR oncology committee white paper.Pediatric blood & cancer · 2023Article
- How does Nephroblastomatosis impact the prognosis of unilateral Wilms tumor?International urology and nephrology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 14 institutions in 2 countries.
Funding
Abstract
introduction
methodsPatients with MIBG-avid high-risk neuroblastoma were eligible. After the first two patients to receive protocol therapy developed severe sinusoidal obstruction syndrome (SOS), the trial was re-designed to include an
resultsFifty-nine of 68 patients (86.8%) who completed induction chemotherapy received
conclusionThis pilot trial demonstrated feasibility and tolerability of administering
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.